Delivery Order SPE2DX22D0010-SPE2D825FHR82
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Nucynta ER (tapentadol extended-release) 100mg tablets, valued at $6,005.43. This firm fixed-price delivery order, which represents a child contract under a larger vehicle, is scheduled for completion by August 5, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open...
- The Defense Logistics Agency awarded a delivery order valued at $2,148.57 to AmerisourceBergen Drug Corp for the supply of Nucynta 75 mg tablets (100 count) on September 23, 2025, with an ultimate completion date of September 24, 2025. This competitive award, which utilized firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX, valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $2,862.27 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Nucynta (tapentadol) 100 mg tablets in a 100-count package. This competitively awarded, non-set-aside contract will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. The delivery order represents a child contract action under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Nucynta ER 100 mg tablets (60-count packages) valued at $1,975.65. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among qualified...
- The Defense Logistics Agency awarded a delivery order valued at $1,788.38 to AmerisourceBergen Drug Corp for Nucynta 100 mg tablets (100 count) on August 20, 2025, with completion scheduled for August 21, 2025. This competitive award, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract employs firm fixed price pricing and represents a relatively small-value transaction within the pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Nucynta ER 100 mg tablets (60-count units) valued at $2,944.08 under a firm fixed-price contract. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling and extends through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a $6,441.19 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Nucynta ER 100 mg tablets (60-count units). This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026. The order will be fulfilled from the contractor's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $13,932.13 for Nucynta Tabs 75mg, a pain management pharmaceutical product. This firm fixed-price delivery order, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a competitive procurement with no set-aside designation. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Nucynta 50 mg tablets (100-count units) with a ceiling value of $1,837.56. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order with an ultimate completion date of September 25, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,848.19 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Nucynta (tapentadol) 50 mg tablets in a quantity of 100 units. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award under the company's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D825FHR82Delivery Order
The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $5,891.14 to AmerisourceBergen Drug Corp for Nucynta ER Tabs 200mg on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order represents a pediatric procurement under a non-competitive set-aside status and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical vendor, holds the Indefinite Delivery Contract SPE2DX with DLA Troop Support Medical valued at $999,999,999.00 and running through December 2026, which serves as the underlying vehicle for this delivery order. This delivery order falls under AmerisourceBergen Drug Corp's expansive pharmaceutical supply agreement with DLA, which enables the company to distribute a comprehensive range of medications and medical supplies to support military healthcare operations globally. Nucynta ER (tapentadol extended-release) is a pain management pharmaceutical used within military and federal healthcare systems. As a child contract under the larger DLA prime vendor agreement, this award reflects the company's ongoing role as a key supplier of controlled substances and specialty medications to federal medical procurement needs, consistent with its extensive portfolio of federal contract awards spanning diabetes medications, neurological treatments, and pain management pharmaceuticals.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 8/15/25 |